Skip to main content
SpringerLink
Log in

Effect of vitamin D on bioavailability and lipid lowering efficacy of simvastatin

  • Original Paper
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Abstract

The 3-hydroxy 3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) inhibitors known as “statins” are widely prescribed for the management of dyslipidemia. In spite of their muscle toxicity, use of statins has alarmingly increased worldwide. A recent report suggests that vitamin D (VD) levels are closely associated with lipid lowering activity and muscular toxicity of statins. However, data are limited and inconclusive. The present study was undertaken to investigate the effect of VD supplementation on the bioavailability and lipid lowering effect of simvastatin (ST). Adult Sprague–Dawley male rats (250 ± 10 g) were divided into four groups including control, ST (100 mg/kg/day), VD (100 μg/kg/day) and ST + VD group, respectively. After the dosing period of 8 days the animals were sacrificed and the blood was collected for the analysis of ST, its active metabolite simvastatin acid (STA), total cholesterol, triglyceride and liver enzymes including aspartate transaminase and alanine transaminase. The result of this study showed a significant decrease in the level of cholesterol and triglyceride in ST alone treated group, whereas VD alone failed to alter the blood lipid levels. Concomitant treatment with VD produced significant decrease in the bioavailability of ST and STA. However, there was no significant difference in the level of cholesterol in ST alone and in ST + VD treated group. Our results on the liver enzyme suggest that ST alone or in combination with VD does not produce any hepatotoxicity. Further studies using VD along with various statins for a longer duration are suggested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Ahmed W, Khan N, Glueck CJ, Pandey S, Wang P, Goldenberg N et al (2009) Low serum 25 (OH) VD levels (<32 ng/ml) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 153:11–16

    Article  CAS  PubMed  Google Scholar 

  • Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, Shiomi M et al (2001) An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103:276–283

    Article  CAS  PubMed  Google Scholar 

  • Al-Otaibi KE, Al Elaiwi AM, Tariq M, Al-Asmari AK (2012) Simvastatin attenuates contrast-induced nephropathy through modulation of oxidative stress, proinflammatory myeloperoxidase, and nitric oxide. Oxid Med Cell Longev 2012:831748

    Article  PubMed Central  PubMed  Google Scholar 

  • Arnaud C, Braunersreuther V, Mach F (2005) Towards immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med 15:202–206

    Article  CAS  PubMed  Google Scholar 

  • Asghar O, Alam U, Hayat SA, Aghamohammadzadeh R, Heagerty AM, Malik RA (2012) Obesity, diabetes and atrial fibrillation; epidemiology, mechanisms and interventions. Curr Cardiol Rev 8(4):253–264

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Barthe L, Woodley J, Houin G (1999) Gastrointestinal absorption of drugs: methods and studies. Fundam Clin Pharmacol 13(2):154–168

    Article  CAS  PubMed  Google Scholar 

  • Bell DS (2010) Resolution of statin-induced myalgias by correcting VD deficiency. South Med J 103:690–692

    Article  PubMed  Google Scholar 

  • Bhattacharyya S, Bhattacharyya K, Maitra A (2012) Possible mechanisms of interaction between statins and VD. QJM 105(5):487–491

    Article  CAS  PubMed  Google Scholar 

  • Carlucci G, Mazzeo P, Biordi L, Bologna M (1992) Simultaneous determination of simvastatin and its hydroxy acid form in human plasma by high-performance liquid chromatography with UV detection. J Pharm Biomed Anal 10(9):693–697

    Article  CAS  PubMed  Google Scholar 

  • Cassel I (2013) The Horrors of Statin Drugs: The Misguided War on Cholesterol, http://www.proliberty.com/observer/20071001.htm. Accessed 11 Aug 2013

  • Chan L, Lowes S, Hirst BH (2004) The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21(1):25–51

    Article  CAS  PubMed  Google Scholar 

  • Chow EC, Durk MR, Cummins CL, Pang KS (2011) 1α, 25-DihydroxyVD3 up-regulates P-glycoprotein via the VD receptor and not farnesoid X receptor in both fxr (−/−) and fxr (+/+) mice and increased renal and brain efflux of digoxin in mice in vivo. J Pharmacol Exp Ther 337(3):846–859

    Article  CAS  PubMed  Google Scholar 

  • Christians U, Strom T, Zhang YL, Steudel W, Schmitz V, Trump S, Haschke M (2006) Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit 28(1):39–44

    Article  CAS  PubMed  Google Scholar 

  • Duell PB, Connor WE (2008) Abstract 3701: VD deficiency is associated with myalgias in hyperlipidemic subjects taking statins. Circulation 118:S470

    Google Scholar 

  • Ebrahim S, Casas JP (2012) Statins for all by the age of 50 years? Lancet 380(9841):545–547

    Article  PubMed  Google Scholar 

  • Eloranta JJ, Hiller C, Jüttner M, Kullak-Ublick GA (2012) The SLCO1A2 gene, encoding human organic anion-transporting polypeptide 1A2, is transactivated by the VD receptor. Mol Pharmacol 82(1):37–46

    Article  CAS  PubMed  Google Scholar 

  • Fromm MF, Busse D, Kroemer HK, Eichelbaum M (1996) Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24(4):796–801

    Article  CAS  PubMed  Google Scholar 

  • Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, Shiomi M (2001) Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 103:993–999

    Article  CAS  PubMed  Google Scholar 

  • Garcia MJ, Reinoso RF, Sanchez Navarro A, Prous JR (2003) Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 25(6):457–481

    Article  CAS  PubMed  Google Scholar 

  • Ginter E, Simko V (2009) Statins: the drugs for the 21st century? Bratisl Lek Listy 110(10):664

    CAS  PubMed  Google Scholar 

  • Goldstein MR, Mascitelli L, Pezzetta F (2009) Statin therapy, muscle function and VD. QJM 102(12):890–891

    Article  CAS  PubMed  Google Scholar 

  • Grimes DS (2009) Statins and vitamin D. Cardiovasc Drugs Ther 23(4):261–262

    Article  PubMed  Google Scholar 

  • Gruer PJ, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA (1999) Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 84(7):811–815

    Article  CAS  PubMed  Google Scholar 

  • Hashizume T, Xu Y, Mohutsky MA, Alberts J et al (2008) Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1α, 25-dihydroxyVD < sub > 3 </sub > conjugation. Biochem Pharmacol 75(5):1240–1250

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Ho RH, Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78(3):260–277

    Article  CAS  PubMed  Google Scholar 

  • Holick MF (2007) Vitamin D deficiency. N Engl J Med 357(3):266–281

    Article  CAS  PubMed  Google Scholar 

  • Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H (1996) The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 24(10):1121–1123

    CAS  PubMed  Google Scholar 

  • Holtzman CW, Wiggins BS, Spinler SA (2006) Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 26(11):1601–1607

    Google Scholar 

  • Huhle G, Abletshauser C, Mayer N, Weidinger G, Harenberg J, Heene DL (1999) Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res 95:229–234

    Article  CAS  PubMed  Google Scholar 

  • Jasiñska M, Owczarek J, Orszulak-Michalak D (2007) Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 59(5):483

    PubMed  Google Scholar 

  • Jerling M, Huan BL, Leung K, Chu N, Abdallah H, Hussein Z (2005) Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol 45(4):422–433

    Article  CAS  PubMed  Google Scholar 

  • Joy TR, Hegele RA (2009) Narrative review: statin-related myopathy. Ann Intern Med 150(12):858–868

    Article  PubMed  Google Scholar 

  • Kanathur N, Mathai MG, Byrd RP Jr, Fields CL, Roy TM (2001) Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 94(9):339–341

    CAS  PubMed  Google Scholar 

  • Kantola T, Kivistö KT, Neuvonen PJ (1998) Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 64(2):177–182

    Article  CAS  PubMed  Google Scholar 

  • Karlgren M, Vildhede A, Norinder U et al (2012) Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug–drug interactions. J Med Chem 55(10):4740–4763

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Khandwala HM (2006) Lipid lowering inefficacy of high-dose statin therapy due to concurrent use of phenytoin. South Med J 99(12):1385–1387

    Article  PubMed  Google Scholar 

  • Kiernan TJ, Rochford M, McDermott JH (2007) Simvastatin induced rhabdomyolysis and an important clinical link with hypothyroidism. Int J Cardiol 119(3):374–376

    Article  PubMed  Google Scholar 

  • Kivistö KT, Niemi M, Schaeffeler E et al (2004) Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenet Genomics 14(8):523–525

    Article  Google Scholar 

  • Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB (1992) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90(5):1871–1878

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ (2000) Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 68(6):592–597

    Article  CAS  PubMed  Google Scholar 

  • Laufs U, La Fata V, Plutzky J, Liao JK (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97:1129–1135

    Article  CAS  PubMed  Google Scholar 

  • Laufs U, Marra D, Node K, Liao JK (1999) 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 274:21926–21931

    Article  CAS  PubMed  Google Scholar 

  • Lee P, Greenfield JR, Campbell LV (2009) Vitamin D insufficiency–a novel mechanism of statin-induced myalgia? Clin Endocrinol 71(1):154–155

    Article  CAS  Google Scholar 

  • Liao JK (2007) Safety and efficacy of statins in Asians. Am J Cardiol 99(3):410–414

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Lilja JJ, Kivistö KT, Neuvonen PJ (1998) Grapefruit juice—simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 64(5):477–483

    Article  CAS  PubMed  Google Scholar 

  • Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Dabhadkar KC (2013) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2095–2128

    Article  Google Scholar 

  • Maxa JL, Melton LB, Ogu CC, Sills MN, Limanni A (2002) Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. Ann Pharmacother 36(5):820–823

    Article  PubMed  Google Scholar 

  • Moyer MW (2012) The stats on statins: should healthy adults over 50 take them? http://www.scientificamerican.com/article.cfm?id=statins-should-healthy- adults- over-50- take- them. Accessed 11 Aug 2013

  • Neuvonen PJ, Niemi M, Backman JT (2006) Drug interactions with lipid lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80(6):565–581

    Article  CAS  PubMed  Google Scholar 

  • Patel BN, Sharma N, Sanyal M, Shrivastav PS (2008) Simultaneous determination of simvastatin and simvastatin acid in human plasma by LC-MS/MS without polarity switch: application to a bioequivalence study. J Sep Sci 31(2):301–313

    Article  CAS  PubMed  Google Scholar 

  • Pe′rez-Castrillo′n JL, Abad Manteca L, Vega G, Del Pino Montes J, de Luis D, Duenas A (2010) Vitamin D levels and lipid response to atorvastatin. Int J Endocrinol 2010:320721

    Google Scholar 

  • Prueksaritanon T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Baillie TA (2002) Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 30(5):505–512

    Article  Google Scholar 

  • Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, Vyas KP (1997) In vitro metabolism of simvastatin in humans (SBT) identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 25(10):1191–1199

    CAS  PubMed  Google Scholar 

  • Reiner Z, Catapano AL, Backer GD, Graham I, Taskinen MR, Wiklund O et al (2011) ESC/EAS Guidelines for the management of dyslipidaemias. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32:1769–1818

    Article  PubMed  Google Scholar 

  • Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC (1998) Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (care) investigators. Circulation 98:839–844

    Article  CAS  PubMed  Google Scholar 

  • Sadeghi R, Adnani N, Erfanifar A, Gachkar L, Maghsoomi Z (2013) Premature coronary heart disease and traditional risk factors-can we do better? Int Cardiovasc Res J 7(2):46–50

    PubMed Central  PubMed  Google Scholar 

  • Schwartz JB (2009) Effects of VD supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clinical Pharmacol Ther 85(2):198–203

    Article  CAS  Google Scholar 

  • Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A (2005) Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 4(8):815–818

    Article  CAS  PubMed  Google Scholar 

  • Sugimoto KI, Ohmori M, Tsuruoka S et al (2001) Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 70(6):518–524

    Article  CAS  PubMed  Google Scholar 

  • Trialists CT (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380(9841):581–590

    Article  Google Scholar 

  • Ucar M, Neuvonen M, Luurila H, Dahlqvist R, Neuvonen PJ, Mjörndal T (2004) Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 59(12):879–882

    Article  CAS  PubMed  Google Scholar 

  • Vickers S, Duncan CA, Vyas KP, Kari PH, Arison B, Prakash SR, Duggan DE (1990) In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 18(4):476–483

    CAS  PubMed  Google Scholar 

  • Walley T, Folino-Gallo P, Stephens P, Van Ganse E (2005) Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003. Br J Clin Pharmacol 60(5):543–551

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Ware WR (2010) The JUPITER lipid lowering trial and VD: is there a connection? Dermatoendocrinology 2(2):50–54

    Article  CAS  Google Scholar 

  • Yeter E, Keles T, Durmaz T, Bozkurt E (2007) Rhabdomyolysis due to the additive effect of statin therapy and hypothyroidism: a case report. J Med Case Rep 1:130

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Center, Prince Sultan Medical Military City, P.O. Box k-486, Riyadh, 11159, Saudi Arabia

    Abdulrahman K. Al-Asmari, Zabih Ullah & Mohammad Tariq

  2. Department of Endocrinology, Prince Sultan Medical Military City, Riyadh, Saudi Arabia

    Fahad Al-Sabaan

  3. Department of Pharmacy, Prince Sultan Medical Military City, Riyadh, Saudi Arabia

    Ahmed Al-Eid

  4. Department of Surgery, Prince Sultan Medical Military City, Riyadh, Saudi Arabia

    Saud F. Al-Omani

  5. Research Center, Prince Sultan Medical Military City, P.O. Box 7897 (S-775), Riyadh, 11159, Saudi Arabia

    Abdulrahman K. Al-Asmari

Authors
  1. Abdulrahman K. Al-Asmari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zabih Ullah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fahad Al-Sabaan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammad Tariq
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ahmed Al-Eid
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Saud F. Al-Omani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abdulrahman K. Al-Asmari.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Al-Asmari, A.K., Ullah, Z., Al-Sabaan, F. et al. Effect of vitamin D on bioavailability and lipid lowering efficacy of simvastatin. Eur J Drug Metab Pharmacokinet 40, 87–94 (2015). https://doi.org/10.1007/s13318-014-0183-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13318-014-0183-z

Keywords

Search

Navigation